Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Isik, B.
Right arrow Articles by Altundag, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Isik, B.
Right arrow Articles by Altundag, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:175, 2004
© 2004 European Society for Medical Oncology

Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: significance of the time between initiation of adjuvant therapy and of therapy for metastatic breast cancer

B. Isik1 and K. Altundag*,2

1 Fatih University Faculty of Medicine, Department of Family Medicine and 2 Hacettepe University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey

*E-mail: drkadri@usa.net

The first 10% of the full text of this article appears below.

We read with interest the article concerning the results of vinorelbine, methotrexate and fluorouracil (VMF) as first line . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?